Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene

Cancer Science

Volumn 95, Issue 2, 2004, Pages 160-167

  Huang, Changxin ^a   Yu, Hai ^a   Wang, Qingqing ^a   Ma, Wenxue ^a   Xia, Dajing ^a   Yi, Pingyong ^a   Zhang, Lihuang ^a   Cao, Xuetao ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENETIC TRANSDUCTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA CELL; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MEMBRANE; ENTEROTOXINS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 1642527106     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03198.x     Document Type: Article

References (55)

1. Jaffee EM, Pardoll DM. Considerations for the critical development of cytokine gene-transduced tumor cell vaccines. Methods 1997; 12: 143-53.
2. Ostrand-Rosenberg S, Pulaski BA, Clements VK, et al. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev 1999; 170: 101-14.
3. Campbell FA, Redmond HP, Bouchier-Hayes D. The role of tumor rejection antigen in host antitumor defense mechanism. Cancer 1995; 75: 2649-55.
4. Beere HM, Green DR. Stress management-heat shock protein 70 and the regulations of apoptosis. Trends Cell Biol 2001; 11: 6-10.
5. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585-8.
6. Wells AD, Malkovasky M. Heat shock proteins, tumor immunogenicity and antigen presentation: An integrated view. Immunol Today 2000; 21: 129-32.
7. Tamura Y, Peng P, Liu K. Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-20.
8. Anthony LS, Wu H, Sweet H, Turnnir C, Boux LJ, Mizzen LA. Priming of CD8+CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 1999; 17: 373-83.
9. Yamazaki K, Nguyen T, Podack ER. Cutting edge: Tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999; 163: 5178-82.
10. Srivastava PK, Heike M. Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation? Semin Immunol 1991; 3: 57-64.
11. Udono H, Srivastava PK. Heat shock protein 70-associated pepetides elicit specific cancer immunity. J Exp Med 1993; 178: 1391-6.
12. Peng P, Menoret A, Srivastava PK. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J Immunol Methods 1997; 204: 13-21.
13. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide- specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315-22.
14. Melcher A, Todryk A. Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-7.
15. Basu S, Srivastava PK. Heat shock proteins: The fountainhead of innate and adaptive immune response. Cell Stress Chaperones 2000; 5: 443-51.
16. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death release heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NFκB pathway. Int Immunol 2000; 12: 1539-46.
17. Moroi Y, Mayhew M, Trcka J, Hoem H, Takecki Y, Hartl FU, Rothman JE, Houghton AN. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000; 97: 3485-90.
18. Asea A, Kraeft SK, Kurt-Jones EA. Stevenson MA, Chen LB, Finberg RN, Koo GC, Calderwood SK. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-42.
19. Menoret A, Chandawarkar R. Heat-shock-protein based anticancer immunotherapy: An idea whose time has come. Semin Oncol 1998; 25: 654-60.
20. White J. The V beta-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989; 56: 27-35.
21. Sogaard M, Ohlsson L, Kristensson K, Rosendahl A, Sjoberg A, Forsberg G, Kalland T, Dohlsten M. Treatment with tumor-reactive Fab-IL-2 and Fabstaphylococcal enteroxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors Int J Oncol 1999; 15: 873-82.
22. Gidlof C, Dohlsten M, Lando P, Kalland T, Sundstrom C, Totterman TH. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Blood 1997; 89: 2089-97.
23. Tordsson JM, Ohlsson LG, Abrahmsen LB, Karlstrom PJ, Lando PA, Brodin TN. Phase-selected primate antibodies fused to superantigen for immunotherapy of malignant melanoma. Cancer Immunol Immunother 2000; 48: 691-702.
24. Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM. Superantigen enhanced protection against a weak tumor-specific melanoma antigen: Implications for prophylactic vaccination against cancer. Int J Cancer 2001; 94: 834-41.
25. Shrayer DP, Kouttab N, Hearing VJ, Wanebo HJ. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer Immunol Immunother 1998; 46: 7-13.
26. Wirth S, Bille F, Koenig S, Wehrli N, Miconnet I, Levy F, Diggelmann H, Romero P, Acha-Orbea H. Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. Int J Cancer 2002; 99: 201-6.
27. Ueno A, Arakawa F, Abe H, Matsumoto H, Kudo T, Asano R, Tsumoto K, Kumagai I, Kuroki M, Kuroki M. T-Cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 2002; 22(2A): 769-76.
28. Newton DW, Dohlsten M, Lando PA, Kalland T, Olsson C, Kotb M. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to antitumor Fab fragments: Implications for use in treatment of human colon carcinoma Int J Mol Med 1998; 1: 157-62.
29. Wang Q, Yu H, Ju DW, He L, Pan JP, Xia Dj, Zhang LH, Cao X. Intratumoral IL-18 gene transfer improve therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Gene Ther 2001; 8: 542-50.
30. Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. J Mol Med 2002; 80: 585-94.
31. Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immunne response. J Cancer Res Clin Oncol 2001; 127: 718-26.
32. Huang AY, Bruce AT, Pardoll DM. Levisky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter Immunity 1996; 4: 349-55.
33. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN. Receptor-mediated uptake of antigen/heat shock protein complexes result in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000; 191: 1957-64.
34. Sondermann H, Becker T, Mayhew M, Wieland F, Hartl FU. Characterization of a receptor for heat shock protein 70 on macrophages and monocytes. Biol Chem 2000; 381: 1165-74.
35. Cho BK, Palliser D, Guillen E, Wisniewski J, Young RA, Chen J, Eisen HN. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 2000; 12: 263-72.
36. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induce Th1 cytokins and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999; 163: 1398-408.
37. Menoret A, Partry Y, Burg C. Cosegregation of tumor immunogenicity with expression of inducible but not constitutive HSP70 in rat colon carcinomas. J Immunol 1995; 155: 740-7.
38. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. HSP72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998; 10: 609-17.
39. Blachere NE, Udono H, Janetzki S. Heat shock protein vaccines against cancer. J Immunother 1993; 14: 352-6.
40. Silverman GJ, Goodyear CS. A model B-cell superantigen and the immunobiology of B lymphocytes Clin Immunol 2002; 102: 117-34.
41. Dellabona P, Peccoud J, Kappler J. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 1990; 62: 1115-21.
42. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-11.
43. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406-14.
44. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA Int J Cancer 1999; 81: 156-63.
45. Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 1998; 160: 5309-13.
46. Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Sogaard M, Andersson J, Andersson U. The distinct role of CD4+ and CD8+ T-cells during the antitumor effects of targeted superantigens. Br J Cancer 1999; 81: 359-66.
47. Holzer U, Bethge W, Krull F. Superantigen staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol Immunother 1995; 41: 129-36.
48. Dohlsten M, Hansson J, Ohlsson L, et al. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 9791-5.
49. Litton MJ, Dohlsten M, Hansson J, Rosendahl A, Ohlsson L, Kalland T, Andersson J, Andersson U. Tumor therapy with an antibody-targeted superantigen generation a dichotomy between local and systemic immune responses Am J Pathol 1997; 150: 703-12.
50. Mondal TK, Bhatta D, Biswas S, Pal P. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide. Biochem Biophys Res Commun 2002; 290: 1336-42.
51. Litton MJ, Dohlsten M, Lando PA. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes,excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 1996; 26: 1-9.
52. Rosendahl A, Hansson J, Sundstedt A. Immune response during tumor therapy with antibody-superantigen fusion proteins Int. J. Cancer 1996; 68: 103-13.
53. Wahlsten JL, Mills CD, Ramakrishnan S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells J Immunol 1998; 161: 6761-7.
54. Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 1988; 9(3): 78-83.
55. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 1998; 8: 657-65.